Investors will shortly be casting a keen eye on the progress of cancer biopharma companies given that the 2019 American Society of Clinical Oncology (ASCO) annual meeting, scheduled to take place in Chicago, is only about a month away. Prior to the release of the meeting abstracts, the presenting public companies will also be reporting their first-quarter earnings and business updates. That means there's no shortage of potential stock valuation-moving events in the near term.